Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis

  • Isidro-Hernández, Marta
  • Mayado, Andrea
  • Casado-García, Ana
  • Martínez-Cano, Jorge
  • Palmi, Chiara
  • Fazio, Grazia
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Raboso-Gallego, Javier
  • Blanco, Óscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Jiménez, Rafael|||0000-0003-4103-8219
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
PAX5 is one of the most frequently mutated genes in B-cell acute lymphoblastic leukemia (B-ALL), and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. Abnormal profiles of inflammatory markers have been detected in neonatal blood spot samples of children who later developed B-ALL. However, how inflammatory signals contribute to B-ALL development is unclear. Here, we demonstrate that Pax5 heterozygosis, in the presence of infections, results in the enhanced production of the inflammatory cytokine interleukin-6 (IL-6), which appears to act in an autocrine fashion to promote leukemia growth. Furthermore, in vivo genetic downregulation of IL-6 in these Pax5 heterozygous mice retards B-cell leukemogenesis, and in vivo pharmacologic inhibition of IL-6 with a neutralizing antibody in Pax5 mutant mice with B-ALL clears leukemic cells. Additionally, this novel IL-6 signaling paradigm identified in mice was also substantiated in humans. Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5-dependent B-ALL and the IL6 as a therapeutic vulnerability for B-ALL characterized by PAX5 loss.